Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis - Top-Institutions - MDSpire

Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis

  • By

  • Zechang Xin

  • Xiaoyu Zhu

  • Hui Qu

  • Xing Ai

  • Kaixuan Wang

  • Xinyue Li

  • Ming Wang

  • Pisong Li

  • Zhongbin Han

  • Ningxin Qu

  • Weiting Yu

  • Hongshen Chen

  • June 10, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Affiliated Zhongshan Hospital of Dalian University
    Affiliated Zhongshan Hospital of Dalian University

    Dalian, Liaoning

    Key Differentiators

    • Oncology

  • #2

    Swedish Cancer Institute
    Swedish Cancer Institute

    Seattle, Washington

    Key Differentiators

    • Oncology

  • #3

    Institut Curie
    Institut Curie

    Paris, Ile-de-France

    Key Differentiators

    • Oncology

  • #4

    The Institute of Cancer Research
    The Institute of Cancer Research

    London, England

    Key Differentiators

    • Oncology

  • #5

    University of California, Irvine
    University of California, Irvine

    Irvine, California

    Key Differentiators

    • Oncology

Original Source(s)

Pretreatment cardiometabolic risk in newly diagnosed breast cancer: a molecular subtype analysis

  • by Zechang Xin, Xiaoyu Zhu, Hui Qu, Xing Ai, Kaixuan Wang, Xinyue Li, Ming Wang, Pisong Li, Zhongbin Han, Ningxin Qu, Weiting Yu, Hongshen Chen

  • June 10, 2026

Related Content

Predicting preoperative axillary lymph node metastasis to guide surgical decisions in invasive breast cancer

Optimizing outcomes with less than more: multi-institutional experience of fast-forward fractionation and the impact of dosimetric parameters on toxicity in breast cancer patients

A multimodal ultrasound-based model combining tumor radiomics and axillary lymph node morphologic classification for predicting axillary nodal burden in breast cancer